



November 25, 2014

## **TG Therapeutics, Inc. to Present at the 2014 Deutsche Bank BioFEST Conference**

NEW YORK, Nov. 25, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced that Michael S. Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 2014 Deutsche Bank BioFEST Conference being held at the Four Seasons Hotel in Boston. Mr. Weiss' presentation is scheduled to take place on Monday December 1, 2014 at 2:50 PM ET. A live audio webcast of this presentation will be available on the Events page, located within the Investors & Media section of the Company's website at [www.tgtherapeutics.com](http://www.tgtherapeutics.com).

### **ABOUT TG THERAPEUTICS, INC.**

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for cancer and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors. TG Therapeutics is headquartered in New York City.

TGTX - G

CONTACT: Jenna Bosco

Director- Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4351

Email: [ir@tgtxinc.com](mailto:ir@tgtxinc.com)



Source: TG Therapeutics, Inc.

News Provided by Acquire Media